Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $199,975.88 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $7.54, for a total value of $199,975.88. Following the transaction, the insider directly owned 4,332,917 shares in the company, valued at approximately $32,670,194.18. This represents a 0.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Wednesday, August 26th, Bioventures 2014 L.P. Mpm sold 14,569 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.06, for a total value of $102,857.14.
• On Monday, August 24th, Bioventures 2014 L.P. Mpm sold 21,623 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.34, for a total value of $158,712.82.

Entrada Therapeutics Trading Down 3.7%

Shares of TRDA stock opened at $7.00 on Friday. The business’s 50 day moving average is $7.08 and its two-hundred day moving average is $9.32. Entrada Therapeutics, Inc. has a twelve month low of $5.02 and a twelve month high of $16.45. The company has a market capitalization of $272.58 million, a P/E ratio of -1.77 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The company had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $2.32 million. As a group, equities analysts predict that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TRDA. State of Wyoming purchased a new stake in shares of Entrada Therapeutics during the 2nd quarter worth $37,000. Russell Investments Group Ltd. grew its stake in shares of Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after purchasing an additional 3,707 shares during the period. Occudo Quantitative Strategies LP purchased a new position in shares of Entrada Therapeutics in the 2nd quarter valued at about $68,000. IHT Wealth Management LLC purchased a new position in shares of Entrada Therapeutics in the 2nd quarter valued at about $72,000. Finally, Jain Global LLC purchased a new position in shares of Entrada Therapeutics in the 3rd quarter valued at about $69,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on TRDA. HC Wainwright cut shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Roth Capital reissued a “buy” rating and set a $11.00 price target on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Guggenheim reduced their price objective on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Finally, Weiss Ratings lowered Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.